GlassScriptPhysician profile
Terri Dee Collins
NPI 1386019800
$666.47
in general payments reported to CMS, 2019-2025
14 companies · $634 in 2025
The $634 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $32.10 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $666.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $154.33 | 2025 | Rexulti |
| Amgen INC. | $108.57 | 2025 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $88.76 | 2024-2025 | Airsupra, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.05 | 2024-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $46.77 | 2025 | Fanapt |
| Exact Sciences Corporation | $40.28 | 2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $32.90 | 2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.90 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $26.90 | 2025 | Invega Sustenna |
| Glaxosmithkline, LLC. | $18.68 | 2025 | Trelegy Ellipta |
| Abbvie INC. | $17.92 | 2025 | |
| Pfizer INC. | $17.12 | 2025 | |
| Esperion Therapeutics, INC. | $14.54 | 2025 | Nexletol |
| Lilly USA, LLC | $13.75 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.